AR019786A1 - Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves - Google Patents

Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves

Info

Publication number
AR019786A1
AR019786A1 ARP990105877A ARP990105877A AR019786A1 AR 019786 A1 AR019786 A1 AR 019786A1 AR P990105877 A ARP990105877 A AR P990105877A AR P990105877 A ARP990105877 A AR P990105877A AR 019786 A1 AR019786 A1 AR 019786A1
Authority
AR
Argentina
Prior art keywords
marek
disease
preparation
birds
virus
Prior art date
Application number
ARP990105877A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR019786A1 publication Critical patent/AR019786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Amplifiers (AREA)

Abstract

Líneas celulares de ave que son una base eficaz para el crecimiento e infeccion productiva del virus de la enfermedad de Marek (MDV) a altasconcentraciones. La presente invencion se refiere también a líneas celulares de aves que se han producido poringeniería genética como bases para elcrecimiento e infeccion productiva de virus de la enfermedad de Marek recombinantes a altas concentraciones. Un procedimiento para la preparacion de virus dela enfermedad de Marek en cantidades adecuadas con fines de preparacion de vacunas.
ARP990105877A 1998-12-09 1999-11-18 Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves AR019786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11162798P 1998-12-09 1998-12-09

Publications (1)

Publication Number Publication Date
AR019786A1 true AR019786A1 (es) 2002-03-13

Family

ID=22339565

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105877A AR019786A1 (es) 1998-12-09 1999-11-18 Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves

Country Status (13)

Country Link
US (2) US6410297B1 (es)
EP (1) EP1038952A3 (es)
JP (2) JP3284118B2 (es)
CN (1) CN1191355C (es)
AR (1) AR019786A1 (es)
AU (2) AU767470B2 (es)
BR (1) BR9905779A (es)
CA (1) CA2289951A1 (es)
HK (1) HK1027595A1 (es)
MX (1) MXPA03009355A (es)
NZ (1) NZ501129A (es)
TW (1) TWI224139B (es)
ZA (1) ZA997114B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
AU2003206861B2 (en) * 2002-02-06 2009-04-23 Lohmann Animal Health Gmbh & Co. Kg A continuous cell line for the production of vaccines
CA2652731A1 (en) * 2008-02-07 2009-08-07 Mark Iv Industries Corp. Real-time location systems and methods
CN103890183A (zh) * 2011-10-21 2014-06-25 英特维特国际股份有限公司 编码传染性喉气管炎病毒和新城疫病毒抗原的重组非致病性马立克氏病病毒构建体
CN103157107A (zh) * 2011-12-14 2013-06-19 普莱柯生物工程股份有限公司 用连续传代细胞系生产鸡马立克氏病疫苗及方法
EP3050572A1 (en) * 2015-01-29 2016-08-03 Ceva Sante Animale Recombinant MDV1 and the uses thereof
US10476549B1 (en) * 2018-05-04 2019-11-12 Futurewei Technologies, Inc. Transmitter linearity built-in-self-test

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8401120A (nl) * 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
FR2719056B1 (fr) * 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
CA2211743A1 (en) * 1995-02-21 1996-08-29 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
EP0748867A1 (en) * 1995-06-12 1996-12-18 Duphar International Research B.V Marek's disease vaccine
US5827738A (en) * 1995-10-27 1998-10-27 Board Of Trustees Operating Michigan State University Sustainable chick cell line infected with Marek's disease virus
US6475770B1 (en) * 1997-06-10 2002-11-05 Pfizer, Inc. Processes for preparation of Marek's Disease using continuous mammalian cell lines

Also Published As

Publication number Publication date
HK1027595A1 (en) 2001-01-19
AU2004200571A1 (en) 2004-03-11
JP2001206854A (ja) 2001-07-31
EP1038952A3 (en) 2001-06-27
CN1191355C (zh) 2005-03-02
BR9905779A (pt) 2001-02-06
EP1038952A2 (en) 2000-09-27
ZA997114B (en) 2001-05-15
CN1256310A (zh) 2000-06-14
MXPA03009355A (es) 2004-03-02
AU5958399A (en) 2000-06-15
AU767470B2 (en) 2003-11-13
JP3626409B2 (ja) 2005-03-09
CA2289951A1 (en) 2000-06-09
JP3284118B2 (ja) 2002-05-20
JP2000166582A (ja) 2000-06-20
US20020132337A1 (en) 2002-09-19
NZ501129A (en) 2001-08-31
TWI224139B (en) 2004-11-21
US6410297B1 (en) 2002-06-25

Similar Documents

Publication Publication Date Title
ECSP066422A (es) Método para obtener factores citotóxicos provenientes de microorganismos, factores citotóxicos obtenidos y composición farmacéutica y conjunto que los contienen.
PE108198A1 (es) Lineas celulares inmortalizadas para el cultivo de virus
EA200200604A1 (ru) Производство вакцин
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
BR9712138A (pt) Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
CY1113138T1 (el) Παραγωγα 10,10-διαλκυλ προστανοϊκου οξεος ως παραγοντες για μειωση ενδο-οφθαλμικης πιεσης
BR9916790A (pt) Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente
AR019786A1 (es) Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves
UY24430A1 (es) Procedimiento para preparar vacuna contra tumores
KR890000105A (ko) 개의 관상 비루스 왁진
Heaney et al. A new genus and species of small ‘tree-mouse’(Rodentia, Muridae) related to the Philippine giant cloud rats
EA200300215A1 (ru) Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой
PT1002055E (pt) Recuperacao de virus a partir de culturas celulares utilizando uma solucao salina hipertonica
ATE56364T1 (de) Lebender gereinigter impfstoff gegen die marek'sche krankheit.
BR0307512A (pt) Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma
HUP0101081A2 (hu) Tápközeg és eljárás vírustenyésztésre és szaporításra
Golenishchev et al. New species of vole of “guentheri” group (Rodentia, Arvicolinae, Microtus) from Iran
MX2022016176A (es) Linea celular para producir una vacuna contra el virus de la enfermedad de marek y metodos para elaborarla y usarla.
KR20000069501A (ko) 뉴우캐슬병에 대한 난내 백신화
MX9602256A (es) Vacuna contra la enfermedad de marek.
MXPA01005808A (es) Cepa de virus de enfermedad bursal infecciosa para administracion en huevo.
AR012944A1 (es) Preparacion de virus de la enfermedad de marek usando lineas de celulas continuas de mamifero
DK1513551T3 (da) Vaccination med immun-isolerede celler, der producerer en immunomodulator
DE69233004D1 (de) Rekombinanter Virus der Marek-Krankheit, Verfahren zur Herstellung dieses Viruses und diesen enthaltender Impfstoff
DZ1550A1 (fr) Vaccin depourvu de cellules contre le virus de la maladie marek.

Legal Events

Date Code Title Description
FB Suspension of granting procedure